New PBS listing dramatically expands immunotherapy access for rare cancers

This includes many rare cancers that previously had no PBS-funded immunotherapy options. For rare cancers where evidence is diverse and situations are heterogeneous this represents a major expansion of therapeutic possibility.

However, it is important to understand that the expanded PBS access does not mean all rare cancers will benefit equally. The ARC Portal is available to support clinicians in these situations where uncertainty can be high, ensuring rational, evidence-based use of these medications.